Muralidhar Beeram

Muralidhar Beeram

UNVERIFIED PROFILE

Are you Muralidhar Beeram?   Register this Author

Register author
Muralidhar Beeram

Muralidhar Beeram

Publications by authors named "Muralidhar Beeram"

Are you Muralidhar Beeram?   Register this Author

31Publications

1031Reads

23Profile Views

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Invest New Drugs 2014 Aug 7;32(4):653-60. Epub 2014 Mar 7.

University of Colorado School of Medicine and Developmental Therapeutics Program, University of Colorado Cancer Center, Mail Stop 8117, RC1 South, Rm 8123, 12801 E. 17th Avenue, Aurora, CO, 80045, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0071-zDOI Listing
August 2014

Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Clin Cancer Res 2007 Jun;13(11):3293-301

Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2496DOI Listing
June 2007

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Clin Cancer Res 2007 Jan;13(2 Pt 1):532-9

Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1606DOI Listing
January 2007

Raf: a strategic target for therapeutic development against cancer.

J Clin Oncol 2005 Sep;23(27):6771-90

University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.08.036DOI Listing
September 2005

Regulation of c-Raf-1: therapeutic implications.

Clin Adv Hematol Oncol 2003 Aug;1(8):476-81

Division of Medical Oncology-Hematology, Institute for Drug Development, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, Zeller Building Z 414-B, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
August 2003

Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.

Hematol Oncol Clin North Am 2002 Oct;16(5):1089-100

Division of Hematology-Medical Oncology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0889-8588(02)00054-0DOI Listing
October 2002